Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Author Archives for Adeline Chauvigné
Valneva and Pfizer complete recruitment for Phase 2 Trial of Lyme disease vaccine candidate
11 May 2025Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
OSE Immunotherapeutics announces voluntary pause of enrollment in the CoVepiT Phase 1 study
OSE Immunotherapeutics today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial... View Article
OSE Immunotherapeutics announces voluntary pause of enrollment in the CoVepiT Phase 1 study
11 May 2025OSE Immunotherapeutics today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial... View Article
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
11 May 2025This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article
Interview with Olivier Boisteau – Vice-President of Clean Biologics and of Atlanpole Biotherapies.
Leader of a group of over 200 people at Clean Biologics, a company offering a range of high-tech services to... View Article
Interview with Olivier Boisteau – Vice-President of Clean Biologics and of Atlanpole Biotherapies.
11 May 2025Leader of a group of over 200 people at Clean Biologics, a company offering a range of high-tech services to... View Article
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux... View Article
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux
11 May 2025Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux... View Article
Valneva continues ongoing discussions with the European Commission for inactivated COVID-19 vaccine candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
Valneva continues ongoing discussions with the European Commission for inactivated COVID-19 vaccine candidate
11 May 2025Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
French biotech XENOTHERA accelerates its development with fundraising of 20 million euros
XENOTHERA is developing a technological platform of exclusive “glyco-humanized” antibodies built on dual expertise in genetics and immunology. The financing... View Article
French biotech XENOTHERA accelerates its development with fundraising of 20 million euros
11 May 2025XENOTHERA is developing a technological platform of exclusive “glyco-humanized” antibodies built on dual expertise in genetics and immunology. The financing... View Article
OSE Immunotherapeutics announces manufacturing agreement with Cenexi for clinical batches of CoVepiT, OSE’s multi-target second-generation COVID-19 vaccine
OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization (CDMO), today announced the signature of an agreement whereby... View Article
OSE Immunotherapeutics announces manufacturing agreement with Cenexi for clinical batches of CoVepiT, OSE’s multi-target second-generation COVID-19 vaccine
11 May 2025OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization (CDMO), today announced the signature of an agreement whereby... View Article
GlioCure strengthens its management team with the recruitment of Dr. Sandrine Courtès as Director of Preclinical Development and Intellectual Property
GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the arrival of Dr. Sandrine Courtès, a researcher-entrepreneur dedicated to brain... View Article
GlioCure strengthens its management team with the recruitment of Dr. Sandrine Courtès as Director of Preclinical Development and Intellectual Property
11 May 2025GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the arrival of Dr. Sandrine Courtès, a researcher-entrepreneur dedicated to brain... View Article
InFlectis BioScience licenses rights to a potential new class of therapies for demyelinating diseases from the University of Chicago
InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment... View Article
InFlectis BioScience licenses rights to a potential new class of therapies for demyelinating diseases from the University of Chicago
11 May 2025InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment... View Article